Shares of the struggling biopharma ImmunoGen skyrocketed today following a clinical update at the American Society of Clinical Oncology meeting. Here’s what you need to know moving forward.
Shares of the struggling biopharma ImmunoGen skyrocketed today following a clinical update at the American Society of Clinical Oncology meeting. Here’s what you need to know moving forward.